Will Biosimilars Reduce Specialty Drug Spending?

National Association of Specialty Pharmacy (NASP) Executive Director James E. Smeeding, RPh, MBA, discusses the potential of biosimilars to reduce the cost burden of specialty pharmaceuticals.

National Association of Specialty Pharmacy (NASP) Executive Director James E. Smeeding, RPh, MBA, discusses the potential of biosimilars to reduce the cost burden of specialty pharmaceuticals.